#cancer immunotherapy market

[trendingreportz]

Cancer Immunotherapy Market - Forecast(2024 - 2030)

Cancer Immunotherapy Market Overview

The Cancer Immunotherapy Market Size is estimated to reach $152.6 billion by 2028 and it is poised to grow at a CAGR of 14.7% over the forecast period of 2023-2028. Cancer immunotherapy is a rapidly growing form of cancer treatment, which is designed to use the body’s own immune system to attack and prevent cancer cells from growing and forming. Immunotherapy carries immense market potential with several pharmaceutical industry companies actively working towards getting FDA approval. Some of the common forms of cancer immunotherapy types are monoclonal antibodies, immunomodulators, cancer vaccines, oncolytic viral therapies and cell therapy. A significant increase in the incidence of various cancer types rightly aids in the growth of the market, as new players are trying to fund various clinical research for advanced treatment. According to World Health Organisation (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. A growing clinical base substantiated by significant investments from private and public players forms a moderate to high industry outlook for the Cancer Immunotherapy Market.

Cancer Immunotherapy Market Report Coverage

The report: “Cancer Immunotherapy Market Forecast (2023-2028)" by IndustryARC, covers an in-depth analysis of the following segments in the Cancer Immunotherapy Market.

By Type: Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators.

By Cancer: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others.

By Route of Administration: Intravenous, Oral, Topical and Intravesical.

By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, Uthe UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Request Sample

Key Takeaways

Geographically, North America held a dominant market share in 2022. It is due to a plethora of market players providing extensive research and development services along with a nuanced and favorable environment for pharmaceutical finances. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028.

A growing population base of cancer across the region supplemented by ailing immunotherapies as a mode to tackle cancer aids market growth. However, extensive usage of other cancer treatments along with the high cost associated with immunotherapies impede the market growth.

A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Cancer Immunotherapy Market Report.

Cancer Immunotherapy Market Segment Analysis - by Type

Cancer Immunotherapy Market based on type can be further segmented into Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators. Monoclonal Antibodies held a dominant market share in 2022 and are estimated to be the fastest-growing type, with a CAGR of 15.9% over the forecast period of 2023-2028. Monoclonal antibodies flag cancer cells, triggers cell-membrane destruction, block cell growth, prevents blood vessel growth and various other function in resolving cancer. This form of treatment methodology is highly prescribed by doctors across the countries due to higher specificity and better cost control along with a safety profile. Moreover, this segment provides a targeted approach that rightly aids market growth. Moreover, as per a recent statement of Bristol Myers Squibb, around a 5% increase in revenues from Opdivo and Yervooy was reported in Q1 2022 against Q1 2021.

Inquiry Before Buying

Cancer Immunotherapy Market Segment Analysis - by Cancer

The Cancer Immunotherapy Market based on cancer type can be further segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others. Lung Cancer held a dominant market share in 2022. It is owing to the high prevalence of this cancer type and the availability and effectiveness of immunotherapy to aid. As per the American Cancer Society, nearly 236,000 new lung cancer cases would be diagnosed in the U.S. in 2022 with high prevalence in older people than younger generations. However, Breast Cancer is estimated to be the fastest-growing cancer type, with a CAGR of 15.7% over the forecast period of 2023-2028. As per BreastCancer.Org, nearly 1 in 8 women in the U.S. would develop cancer each year. Critically, the rampant utilization of drugs such as dostarlimab and pembrolizumab as immune checkpoint inhibitors would aid market growth.

Cancer Immunotherapy Market Segment Analysis - by Geography

North America held a dominant market share of nearly 43% in 2022. This is owing to the presence of a large number of companies. Also, various strategic initiatives are undertaken by both private and public players to eradicate cancer. Active drug regularization from leading authorities allows for the launch in commercial settings which rapidly aids market growth. As per Cancer Statistics Canada 2021, nearly 229,200 cancer cases were diagnosed in the country, with an incidence of 2 in 5 Canadians developing cancer over a lifetime. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028 owing to significant development in regions like Korea, Japan and India which would aid the market participation.

Schedule a Call

Cancer Immunotherapy Market Drivers

Substantial Case Growth in a Variety of Cancer Types:

The proliferation of cancer can start in almost any organ of the body and turn into a malignant form of the disease in no time. As per WHO, cancer is the second leading cause of death globally, with nearly one in six deaths in 2019 alone. Some of the common forms of cancer in men recorded are lung, prostate, colorectal, stomach and liver cancer, whilst breast, colorectal, lung and cervical cancer were the most recorded in women. As per WHO 2020, nearly 2.26 million cases of breast cancer were diagnosed, amongst various other forms of cancer. The usage of immunotherapy rightly aids in market growth.

Substantiated Research and Development Activities Pertinent to Immunotherapy:

A high focus on the development of immunotherapy as a form of treatment for cancer is seen in leading countries, especially, the HDE (Highly Developed Economies). As per Cancer Research Institute UK, nearly $400 million is invested by the organization each year for the prevention, diagnosis and treatment of cancer. Similarly, in 2022, nearly $13 million was granted to Stanford Scientists by U.S. National Cancer Institute and Cancer Research UK for Cancer Treatment. Furthermore, rampant clinical research trials using e-tools have successfully aided in the deployment of immunotherapy as a treatment form. Lastly, around 13 antibody therapeutical drugs were granted approval from 2019-2021 (January) within the EU and the U.S.

Cancer Immunotherapy Market Challenges

High Prevalence of Alternate Treatment Methodologies for Cancer along with Significant Price Challenges:

As per Cancer.Gov, immunotherapy drugs have received wide recognition across the treatment class. However, it is not as widely used as surgery, chemotherapy or radiation therapy. As per Cancer Research UK, nearly 45% of treatment cases for cancer in the United Kingdom opt for surgery; 28% for chemotherapy and nearly 27% for radiotherapy. Furthermore, the cost of utilizing immunotherapy as a treatment method is highly expensive. For example, CAR-T Therapy costs above $475,000 per patient (Kymirah). Similarly, monoclonal antibodies for Nivolumab are $6580 per infusion. These factors hamper the market growth.

Buy Now

Key Market Players

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Cancer Immunotherapy Industry. The top 10 companies in the Cancer Immunotherapy Market are:

Pfizer Inc

Astra Zeneca

Merck and Co

F-Hoffman-La Roche

Bristol Myers Squibb Company

Novartis AG

 Lily

Johnson and Johnson

 Immunocore

BioNTech

Recent Developments

In October 2022, Researchers from the University of Rhode Island and Yale University demonstrated the efficacy of a promising new approach to deliver immunotherapy agents to fight cancer. The approach is known as the Stimulator of Interferon Gene Agonist to an acid-seeking molecule called pH-low insertion peptide.

In October 2022, the FDA approved a new immunotherapy drug for advanced liver cancer. The drug is known as IMJUDO. It is for use in the combination immunotherapy regimen for adults with HCC or Hepatocellular Carcinoma Cancer.

In February 2022, BioNTech and MEDIGENE announced a global collaboration to advance T-cell Receptor Immunotherapies against Cancer. As per the agreement, MEDIGENE would receive EUR 26 million upfront from BioNTech under research funding.

[ashimbisresearch]

Global Cancer Immunotherapy Market Analysis, Trends & Forecast 2028 | BIS Research

The Global Cancer Immunotherapy Market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028 during the forecast period of 2017-2028 and still the market is showing an increase in the ROI in the later years as well.

[univdatosmarket]

Conventional cancer treatments are still the most practiced and the most canonical therapies of today`s medical anti-cancer strategies. They comprise surgery, chemotherapy, and radiation therapy, while cancer immunotherapy is emerging as the new approach that is further being increasingly accepted and has only recently been innovated and approved.

[renubresearch]

Global Cancer Immunotherapy Market

[gauricmi]

The Growing Landscape of the Cancer Immunotherapy Market

A) Market Overview: The global Cancer Immunotherapy Market is estimated to be valued at US$ 93,407.0 million in 2021 and is projected to reach US$ (market value for 2022) million by 2022, exhibiting a CAGR of (given CAGR) % over the forecast period. Cancer immunotherapy involves the use of the body's immune system to fight against cancer cells. This revolutionary approach has gained significant attention and traction in recent years due to its potential to provide a more effective and targeted treatment option for various types of cancers. B) Market Key Trends: With the rapid advancements in medical research and technology, the cancer immunotherapy market is witnessing several key trends. One major trend is the increasing adoption of combination therapies. Researchers and pharmaceutical companies are exploring the synergistic effects of combining different immunotherapies with traditional treatments like chemotherapy and radiation therapy. This approach aims to enhance the overall efficacy of the treatment and improve patient outcomes. For example, the combination of immune checkpoint inhibitors with targeted therapies has shown promising results in certain types of cancer, such as melanoma. The combination of pembrolizumab (Keytruda) and targeted therapy dabrafenib plus trametinib has demonstrated superior progression-free survival rates compared to monotherapy in patients with advanced melanoma. C) Porter's Analysis: Threat of new entrants: The Cancer Immunotherapy Market Growth is highly competitive and characterized by a significant level of research and development investments. The high cost of drug development, regulatory requirements, and complex manufacturing processes act as barriers to entry for new players. Bargaining power of buyers: Due to the vital nature of cancer treatments, buyers (such as healthcare institutions and patients) have limited bargaining power. The demand for effective and safe cancer immunotherapies outweighs the influence of buyers to negotiate lower prices. Bargaining power of suppliers: Suppliers in the cancer immunotherapy market, including pharmaceutical companies and contract manufacturing organizations, hold a stronger bargaining power. They possess the expertise and resources required for drug development, production, and distribution. Threat of new substitutes: While traditional treatments like chemotherapy and radiation therapy remain prevalent, the advent of cancer immunotherapy has provided an innovative and promising alternative. The development of effective immunotherapies reduces the threat of substitutes for cancer treatments. Competitive rivalry: The cancer immunotherapy market is highly competitive, with several key players vying for market share. Novartis AG, Merck & Co. Inc., F-Hoffmann La Roche, Eli Lilly and Company, Bayer AG, AstraZeneca, Astellas Pharma Inc., Amgen Inc., OSE Immunotherapeutics SA, and Bristol-Myers Squibb Company are among the leading companies operating in this space. These players invest extensively in research and development to innovate new therapies and gain a competitive edge. D) Key Takeaways: The global cancer immunotherapy market is expected to witness high growth, exhibiting a CAGR of (given CAGR) over the forecast period, driven by the increasing prevalence of cancer and the growing demand for effective and targeted treatment options. The rise in investments in research and development activities, as well as the collaboration between pharmaceutical companies and research institutes, are also contributing factors. Regionally, (mention the fastest-growing and dominating region) is projected to dominate the cancer immunotherapy market due to its well-established healthcare infrastructure, favorable reimbursement policies, and a high prevalence of cancer cases. Additionally, the increasing focus of key players on expanding their presence in emerging markets, such as (mention specific emerging markets), is expected to further fuel the market growth.

[writerblogs]

 Cancer Immunotherapy Market - A Global Analysis

 The field of oncology has been undergoing a paradigm shift with the emergence of Cancer Immunotherapy, a groundbreaking approach that harnesses the power of the immune system to combat cancer. The Cancer Immunotherapy Market has been rapidly evolving, driven by promising clinical outcomes and innovative research efforts. Let's take a closer look at the current landscape and future prospects of this dynamic market.

Market Overview:

The Cancer Immunotherapy Market has witnessed significant growth in recent years, and this trend is projected to continue. Traditional cancer treatments like chemotherapy and radiation therapy have limitations and often come with severe side effects. In contrast, immunotherapy offers a more targeted approach, enabling the immune system to recognize and eliminate cancer cells while sparing healthy tissues.

Key Players and Therapies:

Several pharmaceutical and biotechnology companies are at the forefront of developing cancer immunotherapies. Notable therapies include checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and immune checkpoint modulators. Checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable success in various cancer types by blocking the proteins that prevent immune cells from attacking cancer cells.

Clinical Success Stories:

The Cancer Immunotherapy Market has witnessed groundbreaking success stories. Patients with advanced melanoma, lung cancer, and other malignancies have experienced prolonged survival and even complete remission, thanks to immunotherapy. These outcomes have not only transformed patients' lives but have also boosted investor confidence and research funding.

Challenges and Opportunities:

While the Cancer Immunotherapy Market holds immense promise, it also faces challenges. Not all patients respond equally to immunotherapy, and there is a need to identify biomarkers that predict treatment response. Moreover, the high cost of these therapies can limit accessibility for some patients. However, these challenges create opportunities for collaboration, research, and the development of more cost-effective treatment options.

Future Directions:

The Cancer Immunotherapy Market is poised for continuous innovation. Researchers are exploring combination therapies to enhance the efficacy of immunotherapy, as well as investigating its potential in treating a wider range of cancer types. Additionally, advancements in personalized medicine will likely lead to tailored immunotherapy regimens based on patients' genetic profiles and immune system characteristics.

[futuretonext]

The Global Cancer Immunotherapy Market is projected to grow at a CAGR of around 13.22% during the forecast period, i.e., 2023-28

[creativeera]

Bone Cancer Drugs Market is driven by growing demand for targeted therapies

The global Bone Cancer Drugs market is primarily driven by the increasing prevalence of cancer including bone tumor or bone cancer. Bone cancer drugs help in treating cancer that starts in the bones, such as osteosarcoma or Ewing's sarcoma. Bone cancer drugs include molecular target drugs, chemotherapy and others that help inhibit or block the growth of cancer cells. Bone cancer drugs are used for treating primary bone tumors and metastatic bone tumors. Primary bone tumors start within the bones whereas metastatic bone tumors spread to the bones from other parts of the body. Bone cancer drugs block the growth of cancer cells by interfering with cell division or inducing cell death. The increasing adoption of targeted therapies including monoclonal antibodies and small molecule inhibitors are helping treat various types of cancers more efficiently with lesser side effects. The growing prevalence of bone cancer coupled with availability of advanced targeted therapies are the major factors driving the growth of the global bone cancer drugs market.

The Global Bone Cancer Drugs Market is estimated to be valued at US$ 1423.67 Mn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Bone Cancer Drugs market are Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical. The demand for bone cancer drugs is increasing globally due to rising prevalence of primary bone tumors as well as bone metastasis. According to cancer research UK, around 2,300 new bone cancer cases are reported each year in the UK. The increasing incidences of bone metastasis from cancers originating in breasts, lungs and prostate is a major factor driving the Bone Cancer Drugs Market Size. According to American Cancer Society, over 170,000 new cases of breast cancer are expected to be diagnosed in 2021 in the US, out of which approximately 40,000 will develop bone metastases. The global companies are expanding their presence into emerging markets of Asia Pacific, Middle East and Latin America to tap the growth opportunities in these regions. Market key trends The Bone Cancer Drugs market is witnessing trend of availability of personalized medicines. With advancement in understanding of genetics and specific mutations driving cancers, targeted therapies are being developed that can identify unique mutations in an individual patient's cancer and target them precisely. This enables delivering the right treatment to the right patient and optimizing treatment outcomes. Companies are investing heavily in development of novel targeted therapies and companion diagnostics that help deliver personalized cancer care. This trend is expected to significantly influence the bone cancer treatment landscape and support market growth over the forecast period. Porter’s Analysis Threat of new entrants: High research and development costs and regulatory barriers related to clinical trials make it difficult for new companies to enter the bone cancer drugs market. Bargaining power of buyers: Patients have limited bargaining power due to serious nature of disease. However, availability of alternative treatment options provide some bargaining power. Bargaining power of suppliers: Established drug manufacturers have significant bargaining power due to their large product portfolios and scarce manufacturing capabilities. Threat of new substitutes: Alternatives like chemotherapy and radiation therapy impose a moderate threat as bone cancer drugs aim to target tumors specifically. Competitive rivalry: Potential for high profits drives major pharmaceutical companies to intensely compete through intensive research and clinical trials. Geographically, North America is currently dominating the bone cancer drugs market in terms of value owing to high prevalence, increasing healthcare expenditure and presence of major players. The market in Asia Pacific is projected to witness the fastest growth over the forecast period due to growing healthcare infrastructure, large patient pool and rising disposable income in developing countries. Another major geographical region concentrated with bone cancer drugs market is Western Europe. Countries like Germany, United Kingdom and France collectively account for highest market share due to well-developed healthcare systems and availability of favorable reimbursement policies.

Get more insights on Bone Cancer Drugs Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[trendtrackershq]

𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐚𝐧𝐝 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬! 

𝐆𝐞𝐭 𝐚 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞: https://www.nextmsc.com/cancer-vaccines-market/request-sample

As we delve deeper into the realm of oncology, the spotlight shines brightly on the promising horizon of 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬.

𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: Innovations in biotechnology and genetic engineering are driving the development of novel cancer vaccine platforms, offering tailored solutions for different cancer types.

𝐑𝐢𝐬𝐢𝐧𝐠 𝐈𝐧𝐜𝐢𝐝𝐞𝐧𝐜𝐞: The escalating burden of cancer worldwide underscores the urgent need for effective preventive and therapeutic interventions, positioning cancer vaccines as a pivotal tool in the fight against malignancies.

𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧: Cancer vaccines represent a cornerstone of immunotherapy, harnessing the body's immune system to recognize and eradicate cancer cells with precision, paving the way for more targeted and durable treatment outcomes.

𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬: Robust clinical pipelines are fueling optimism, with a myriad of cancer vaccine candidates undergoing rigorous evaluation across various stages of clinical trials, offering hope for patients and healthcare providers alike.

𝐅𝐮𝐭𝐮𝐫𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: As we navigate the evolving landscape of cancer care, the advent of cancer vaccines holds immense promise in reshaping treatment strategies, fostering hope for improved patient outcomes, and ultimately, steering us closer to our collective goal of conquering cancer.

𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.nextmsc.com/report/cancer-vaccines-market

𝐕𝐚𝐫𝐢𝐨𝐮𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐩𝐥𝐚𝐲𝐞𝐫𝐬: GlaxoSmithKline plc, UbiVac, Inc, Biontech, Dendreon Pharmaceuticals, Inc, Dynavax Technologies Corporation, Merck & Co., Inc, Imugene Limited, Moderna, Inc, Northwest Biotherapeutics, Inc., and Oxford Vacmedix.

[laxmandige05]

The global cancer immunotherapy drug discovery outsourcing market size was exhibited at USD 2.33  billion in 2023 and is projected to hit around USD 5.87 billion by 2032, growing at a CAGR of 10.8% during the forecast period 2023 to 2032.

[marketreports-blog]

The global cancer immunotherapy drug discovery outsourcing market size was exhibited at USD 2.11 billion in 2022 and is projected to hit around USD 5.87 billion by 2032, growing at a CAGR of 10.8% during the forecast period 2023 to 2032.